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Abstract
Background: Persistent hyperlactatemia during septic shock is multifactorial. Hypoperfusion-related anaerobic
production and adrenergic-driven aerobic generation together with impaired lactate clearance have been
implicated. An excessive adrenergic response could contribute to persistent hyperlactatemia and adrenergic
modulation might be beneficial. We assessed the effects of dexmedetomidine and esmolol on hemodynamics,
lactate generation, and exogenous lactate clearance during endotoxin-induced septic shock.
Methods: Eighteen anesthetized and mechanically ventilated sheep were subjected to a multimodal
hemodynamic/perfusion assessment including hepatic and portal vein catheterizations, total hepatic blood flow,
and muscle microdialysis. After monitoring, all received a bolus and continuous infusion of endotoxin. After 1 h
they were volume resuscitated, and then randomized to endotoxin-control, endotoxin-dexmedetomidine
(sequential doses of 0.5 and 1.0 μg/k/h) or endotoxin-esmolol (titrated to decrease basal heart rate by 20 %) groups.
Samples were taken at four time points, and exogenous lactate clearance using an intravenous administration of
sodium L-lactate (1 mmol/kg) was performed at the end of the experiments.
Results: Dexmedetomidine and esmolol were hemodynamically well tolerated. The dexmedetomidine group
exhibited lower epinephrine levels, but no difference in muscle lactate. Despite progressive hypotension in all
groups, both dexmedetomidine and esmolol were associated with lower arterial and portal vein lactate levels.
Exogenous lactate clearance was significantly higher in the dexmedetomidine and esmolol groups.
Conclusions: Dexmedetomidine and esmolol were associated with lower arterial and portal lactate levels, and less
impairment of exogenous lactate clearance in a model of septic shock. The use of dexmedetomidine and esmolol
appears to be associated with beneficial effects on gut lactate generation and lactate clearance and exhibits no
negative impact on systemic hemodynamics.
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Background
Persistent hyperlactatemia during septic shock resuscita-
tion is associated with very high mortality and has been
considered a hallmark of impending tissue hypoxia [1–8].
Therefore, some current guidelines recommend targeting
resuscitation at normalizing lactate levels [4]. In clinical
practice, this is accomplished by increasing cardiac output
(CO) with fluid loading and/or inodilators [8, 9].
The paradigm of hypoxic-generated lactate has been
recently challenged [1, 5]. Indeed, serum lactate levels
during septic shock resuscitation represent a balance be-
tween aerobic or anaerobic generation, and clearance by
different tissues. Consistent translational research has
shown that muscle lactate generation can be triggered
by epinephrine through β2-receptor stimulation, a
process denominated aerobic glycolysis [10, 11]. On the
other hand, an impaired lactate clearance might be
present even without obvious signs of liver ischemia [12,
13]. In a recent experimental study, we found an early
and severe impairment of exogenous lactate clearance to
10 % of sham values 1 hour after endotoxic [lipopolysac-
charide (LPS)] shock induction [13]. This finding was
not explained by liver hypoperfusion as tested with dif-
ferent techniques [13], although the pathogenic mecha-
nisms were not explored. It is important to emphasize
that in this study we addressed real clearance, applying a
kinetic modeling after an intravenous (IV) bolus of so-
dium lactate that describes its elimination from the body
over a short period of time [13]. The term “lactate clear-
ance” has somehow been erroneously used in medical
literature because a decrease in serum lactate levels
could be caused either by a decreased production or in-
creased clearance, and the inverse is also true [13, 14].
On the other hand, an overwhelming adrenergic re-
sponse could contribute to persistent hyperlactatemia.
Excessive α-mediated vasoconstriction might hasten hy-
poperfusion particularly in the hepatosplanchnic region,
consequently increasing gut anaerobic lactate produc-
tion, and impairing hepatic clearance by reducing portal
or intrahepatic microcirculatory blood flow or eventually
through metabolic effects [15–21]. High epinephrine
levels can exacerbate aerobic glycolysis [10, 11]. The in-
creasing awareness of the toxicity of sustained hypera-
drenergia in critical illness has led to exploring
adrenergic modulation or blockade as potential targets
to attenuate adverse hemodynamic, microcirculatory,
metabolic, and pro-inflammatory effects of sympathetic
overstimulation [22–26]. Indeed, adrenergic modulation
with an α2-agonist such as dexmedetomidine (DEX)
[27–34], or β-blockers like esmolol (ESM) [35–40] have
demonstrated favorable effects on diverse physiological
and clinical outcome parameters in septic shock, and
also on some potential determinants of persistent
hyperlactatemia.
However, most of the studies with adrenergic modula-
tion or β-blockade have been performed after the initial
resuscitation period, and it is not known if these therap-
ies are tolerated earlier in the evolution. In addition,
since hyperlactatemia is a fundamental target for septic
shock resuscitation, and due to the adrenergic influence
over its determinants, it could be relevant to explore the
impact of adrenergic modulation or β-blockade at this
level. To address this subject, we performed a controlled
experimental study in an endotoxic sheep model [13]
aimed at (1) determining the effects of DEX and ESM as
compared to LPS-control animals on lactate production
and exogenous lactate clearance; and (2) evaluating the
hemodynamic tolerance of DEX and ESM in the very
early phase of septic shock. We hypothesized that both
dexmedetomidine and esmolol decrease lactate produc-
tion and attenuate impairment in exogenous lactate
clearance in this model.
Methods
The experimental design was performed in agreement
with the Guide for the Care and Use of Laboratory Ani-
mals, 8th edition (2011), and with the approval of the
Comité de Etica y Bienestar Animal of the Pontificia
Universidad Católica de Chile (CEBA 12-031). We used
a well-standardized model of LPS shock in sheep that in-
duces a characteristic hyperdynamic profile [13]. Details
of the experimental setup have been reported elsewhere
and will be summarized below [13].
Our model addressed three of the major determinants
of persistent hyperlactatemia: muscle lactate generation
as potentially representing adrenergic-driven aerobic gly-
colysis through microdialysis and serum epinephrine
levels; gut lactate production as potentially representing
anaerobic generation through portal oxygen venous sat-
uration and lactate levels; and clearance using the ex-
ogenous lactate clearance technique proposed by
Levraut et al [12].
Animal care and anesthesia
Sheep weighing 32 ± 5.2 kg were used. Animals were
fasted 12 h before the experiments but with free access
to water. Sheep were premedicated with 20 mg/kg keta-
mine and 0.25 mg/kg midazolam intramusculary. After
inserting a peripheral intravenous line and injecting 30
mcg/kg fentanyl + 0.5 mg/kg atracurium + 1 mg/kg lido-
caine intravenously, sheep were intubated and connected
to mechanical ventilation in volume-control mode
(Savina® 300, Dräger, Lübeck, Germany) with a tidal vol-
ume of 10 ml/kg. Anesthesia was sustained with a con-
tinuous infusion of midazolam, fentanyl, and ketamine.
Muscle relaxation was maintained with a continuous
atracurium infusion. During the surgical procedure, nor-
mal saline was infused at 10 ml/kg/h, and the rate was
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reduced to 5 ml/kg/h thereafter till the end of the ex-
periment. Body temperature was kept at 38 ± 0.5 °C.
Surgery and instrumentation
An 8-Fr sheath was placed in both the left and right exter-
nal jugular veins to advance pulmonary artery and hepatic
vein catheters, respectively. The latter were positioned
under ultrasound guidance. The left femoral artery and
vein were surgically exposed, and arterial and central ven-
ous catheters were introduced for blood pressure monitor-
ing, sampling, and administering fluids and drugs.
The abdomen was opened via a midline laparotomy
and gastric contents were drained through a small
gastrostomy. After this, the splenic vein was ligated
and a portal catheter was placed for sampling. An
ultrasound flow probe (Transonic, Ithaca NY, USA)
was positioned around the hepatic artery and the por-
tal vein to measure total hepatic blood flow, and the
laparotomy was closed. A microdialysis catheter was
inserted in the anterior quadriceps muscle (Harvard
Apparatus, Holliston MA, USA).
Measurements
1. Hemodynamic data were recorded every 30 minutes:
heart rate (HR), mean arterial pressure (MAP), pulse
pressure variation (PPV), and pulmonary arterial and
occlusion pressures were measured with the
standard procedure and displayed on a multi-
modular monitor (GE Healthcare, Datex-Ohmeda,
Madison WI, USA). CO was assessed by thermodilu-
tion (CO module, GE Healthcare, Datex-Ohmeda,
Madison WI, USA).
2. Systemic and hepatosplanchnic oxygen delivery and
consumption: arterial, portal vein, hepatic vein, and
mixed venous gases were assessed with a blood gas
analyzer (i-Stat® bedside gas analyzer, Abbott
Laboratories, Princeton NJ, USA). Total hepatic
blood flow was measured with the ultrasound flow
probe.
3. Lactate assessment: serum lactate levels at every
experimental time point were obtained from arterial
and venous blood samples, and measured directly
with a lactate scout monitor (Senslab, Leipzig,
Germany). Measurements were performed in
triplicate and results were averaged.
4. Exogenous lactate clearance: lactate clearance was
performed at the end of the experiment. An
intravenous dose of sodium L-lactate (1 mmol/kg)
was infused via the central venous catheter in 15 mi-
nutes [13]. Arterial blood samples were obtained at
baseline and 1, 3, 6, 9, 15, and 20 minutes thereafter.
Clearance was later calculated by the least squares
technique with semi-logarithmic coordinates [13].
5. Muscle microdialysis was performed using a CMA/
402 microinjection pump at 0.3 μL/min of perfusion
flow rate coupled to the microdialysis probe CMA/
20 (Harvard Apparatus, Holliston, MA, USA). A 1-h
equilibration period was allowed after insertion of
the probe. The dialysate was collected into sealed
250 μL glass tubes in a refrigerated (4 °C) fraction
collector (CMA142). Dialysate fractions for lactate
assessment were collected during the last 30 minutes
before time points A to D (Fig. 1, see below).
6. Epinephrine levels: serum epinephrine levels were
determined in duplicate with an enzyme
immunoassay kit (Rock Mountain Diagnostics,
Colorado Springs, CO, USA).
Experimental protocol
After 1 h of postsurgical stabilization, basal measure-
ments were performed (Fig. 1, point A). Then, septic
shock was induced by administration of a 5 μg/kg LPS
IV bolus (E coli 0111: β4; Millipore Sigma, St. Louis
MO, USA) followed by a continuous LPS infusion at
4 μg/kg/h until the end of the experiment. During the
first hour of LPS infusion no fluids or vasopressors were
administered. Thereafter, resuscitation was performed
with 5 ml/kg IV normal saline boluses repeated up to
three times until a MAP of 55 to 60 mmHg or a pulse
pressure variation below 10 % was achieved. If fluid
loading failed to reestablish the MAP goal, norepineph-
rine (NE) was started at 0.1 mcg/kg/min and titrated in
0.1 mcg/kg/min increments every 5 minutes to the MAP
target. Repeated series of measurements were performed
after resuscitation (point B), and 1 and 2 h later (Fig. 1,
points C and D, respectively). At each time point
hemodynamic and respiratory variables, blood
temperature, total hepatic blood flow, and arterial,
mixed-venous, portal, and hepatic vein blood gases and
lactate samples were taken simultaneously. Between
points B and D, hypotension was basically managed with
NE increments, but when the dose was increased by
A B C D
Experimental 
Setup
Stabilization
period
LPS infusion
Saline Saline
0.5 µg·kg  ·h 1 µg·kg  ·h
Dose to HR reduction 20-30%
1) Control
2) DEX
3) ESM
randomized
1 h 1 h 1 h 1 h
resuscitation
Fig. 1 General scheme of the protocol. Complete hemodynamic,
respiratory, and systemic and regional perfusion measurements were
performed at points A, B, C, and D, except for lactate clearance that was
performed at point D. LPS lipopolysaccharide, DEX dexmedetomidine,
ESM esmolol, HR heart rate
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>0.5 mcg/kg/min during a 30-minute interval, and PPV
was >15 % an additional 5 ml/kg fluid bolus was
indicated.
After recording data set at point B, sheep were ran-
domized into three groups of six animals each, LPS con-
trol, LPS-DEX (Precedex®, Hospira, Inc., Lake Forest, IL,
USA), and LPS-ESM (Baxter Healthcare Corporation,
Deerfield, IL, USA). To save animals and experiments
we used only one LPS-control group against which DEX
and ESM groups could be later compared. DEX was ad-
ministered in two fixed doses for a 1-h period each (after
point B, 0.5 μg/kg/h and after point C, 1.0 μ/kg/h). ESM
was started at 15 mg/h and titrated every 5 minutes to
achieve a reduction of 20–30 % in relation to HR at
point B. This HR target was maintained until point D.
Animals were euthanized with thiopental at the end of
the experiment.
Statistics
All data are presented as mean ± standard deviation
(SD). Statistical testing was two-sided and used the 5 %
significance level.
We calculated that six animals would be required per
arm to detect a significant difference of 1.8 mmol/l in
serum lactate levels, with a sigma of 1.0 mmol/l,
between LPS-control and LPS-DEX or LPS-ESM groups,
assuming a type I error rate of 5 % and a power of 80 %.
This calculation was based upon data from a previous
study in which after 150 minutes of evolution, LPS ani-
mals presented a mean lactate of 3.7 + 0.9 mmol/l as
compared with 1.3 + 0.3 mmol/l in controls [41].
The Shapiro-Wilk test was used to test for normality,
with p values > 0.10 indicating a normal distribution.
Comparisons of different time points within a single
group (A, B, C and D) were performed by using Fried-
man’s test with Bonferroni’s post hoc correction. Com-
parisons of continuous variables between two groups
were conducted with the t test or the Mann-Whitney U
test, as appropriate.
Since the main objective of our study was to explore
the individual impact of two anti-adrenergic interven-
tions on the main determinants of persistent hyperlacta-
temia, we only performed comparisons between LPS-
control and LPS-DEX groups, and between LPS-control
and LPS-ESM groups, but not between the study drugs.
Statistical analysis was performed using STATA version
11.0 (StataCorp LP, College Station, TX, USA).
Results
LPS induced a progressive septic shock with systemic
hypotension, pulmonary hypertension and increasing NE
requirements without differences between groups
(Tables 1 and 2). DEX and ESM were well tolerated, and
not associated with any adverse hemodynamic effect in
terms of CO, mixed venous O2 saturation (SvO2), mixed
venous-arterial carbon dioxide partial pressure gradients
(p(v-a) CO2) or changes in NE requirements as com-
pared to LPS controls (Tables 1 and 2). As expected
LPS-ESM sheep exhibited a significant lower HR than
LPS controls. The mean ESM dose was 26.7 ± 16.7 mg/h
at point C and 32.2 ± 33.9 mg/h at point D.
LPS induced a progressive hyperlactatemia in the three
groups, although serum lactate levels at point C were
lower with DEX and ESM as compared to controls. This
effect was maintained for ESM at point D (Table 3).
DEX group exhibited significant lower epinephrine levels
as compared to controls at point D (Table 3). No differ-
ence in muscle lactate production between groups was
observed.
Portal lactate levels increased over time in all animals,
but both DEX and ESM groups presented significant
lower portal lactate values at points C and D as com-
pared to LPS controls (Table 4). Exogenous lactate clear-
ance was significantly higher in both DEX and ESM
groups at point D (LPS-control 2.43 ± 1.14, LPS-DEX
6.97 ± 1.60, LPS-ESM 7.32 ± 2.2 ml/kg/min; p < 0.05)
(Table 3 and Fig. 2). Total hepatic blood flow was com-
parable between groups (Table 4 and Fig. 2).
Discussion
The use of dexmedetomidine and esmolol was associ-
ated with lower arterial and portal lactate levels, and less
impairment of exogenous lactate clearance in a model of
septic shock. Both drugs were well tolerated when
started very early after shock induction. DEX and ESM
appear to be associated with beneficial effects on gut lac-
tate generation and exogenous lactate clearance, and
exhibit no negative impact on systemic hemodynamics.
Dexmedetomidine, an α2-agonist, attenuates sympa-
thetic response to stress, and lowers epinephrine levels
without adverse consequences on tissue perfusion [27–
34]. Several experimental studies have consistently found
anti-inflammatory effects and improvement in microcir-
culatory flow [32–34]. The drug is relatively well toler-
ated in anesthetized or critically ill patients, and even a
post hoc analysis of the MENDS trial suggests an impact
on mortality in septic patients [31]. Therefore, it could
be useful as an adrenergic modulator in this setting.
On the other hand, the supporting evidence for β-
blockers in sepsis is weak. Some small experimental and
clinical studies have shown favorable effects on HR and
hemodynamic or perfusion parameters, and also in in-
flammatory and metabolic parameters, particularly with
nonselective blockers since most of these latter effects
are β2 mediated [35]. However, β1 blockade could also
exert anti-inflammatory effects, as was demonstrated by
Hagiwara et al in a LPS rat model, on which an ultrashort-
acting β-blocker inhibited nuclear factor-kappa B activity
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Table 1 Comparison of hemodynamic variables between LPS-control and LPS-DEX group along the study period
Variable Group A B C D pa
HR (bpm) Control 127 ± 25 143 ± 16 137 ± 15 125 ± 20
DEX 139 ± 14 146 ± 27 128 ± 32 129 ± 30
MAP (mmHg) Control 88 ± 14 67 ± 14 59 ± 5 61 ± 7 a
DEX 99 ± 20 63 ± 6 62 ± 12 58 ± 13 a
CO (ml/kg/min) Control 78.3 ± 12.7 90.6 ± 26.4 80.0 ± 29.5 75.1 ± 23.1
DEX 89.0 ± 27.2 109 ± 21.2 92.1 ± 28.2 72.0 ± 25.9
MPAP (mmHg) Control 14 ± 2 20 ± 4 23 ± 9 23 ± 10 a
DEX 13 ± 3 19 ± 7 21 ± 6 28 ± 5 a
PAOP (mmHg) Control 8 ± 1 8 ± 1 7 ± 1 7 ± 1
DEX 9 ± 3 6 ± 2 7 ± 2 7 ± 3
SvO2 (%) Control 74 ± 4.5 78 ± 7.0 74 ± 10 69 ± 9.3
DEX 75 ± 5.5 77 ± 5.9 72 ± 5.9 68 ± 12
P(v-a)CO2 (mmHg) Control 4.7 ± 2.9 4.4 ± 3.6 6.9 ± 4.6 5.8 ± 4.0
DEX 4.1 ± 3.7 4.2 ± 1.8 3.5 ± 2.0 7.1 ± 1.1
NE (μg/kg/min) Control 0.77 ± 0.52 1.34 ± 0.6 1.88 ± 1.31 a
DEX 1.08 ± 0.36 1.46 ± 0.38 1.62 ± 0.45 a
Values are presented as mean ± standard deviation (SD)
LPS lipopolysaccharide, DEX dexmedetomidine, HR heart rate, MAP mean arterial pressure, CO cardiac output, MPAP mean pulmonary arterial pressure, PAOP
pulmonary artery occlusion pressure, SvO2 mixed venous oxygen saturation, p(v-a)CO2 mixed venous to arterial carbon dioxide partial pressure gradient,
NE norepinephrine
p < 0.05 considered as significant
aSignificant changes over time within groups (comparison made with Friedman test and post hoc Bonferroni correction)
Table 2 Comparison of hemodynamic variables between LPS-control and LPS-ESM groups along the study period
Variable Group A B C D pa
HR (bpm) Control 127 ± 25 143 ± 16 137 ± 15 125 ± 20
ESM 128 ± 19 133 ± 17 109 ± 12* 105 ± 9* a
MAP (mmHg) Control 88 ± 14 67 ± 14 59 ± 5 61 ± 7 a
ESM 90 ± 18 70 ± 16 60 ± 8 76 ± 6 a
CO (ml/kg/min) Control 78.3 ± 12.7 90.6 ± 26.4 80.0 ± 29.5 75.1 ± 23.1
ESM 69.0 ± 17 101 ± 32.0 84.0 ± 29.6 82.7 ± 28.4
MPAP (mmHg) Control 14 ± 2 20 ± 4 23 ± 9 23 ± 10 a
ESM 16 ± 3 22 ± 7 22 ± 8 24 ± 7 a
PAOP (mmHg) Control 8 ± 1 8 ± 1 7 ± 1 7 ± 1
ESM 7 ± 2 8 ± 2 8 ± 2 9 ± 2
SvO2 (%) Control 74 ± 4.5 78 ± 7.0 74 ± 10 69 ± 9.3
ESM 71 ± 5.1 73 ± 9 65 ± 11 65 ± 15
P(v-a)CO2 (mmHg) Control 4.7 ± 2.9 4.4 ± 3.6 6.9 ± 4.6 5.8 ± 4.0
ESM 5.2 ± 5.1 5.2 ± 3.2 7.2 ± 3.1 7.1 ± 4.0
NE (μg/kg/min) Control 0.77 ± 0.52 1.34 ± 0.6 1.88 ± 1.31 a
ESM 0.87 ± 0.61 1.42 ± 0.61 1.52 ± 0.27 a
Values are presented as mean ± standard deviation (SD)
LPS lipopolysaccharide, ESM esmolol, HR heart rate, MAP mean arterial pressure, CO cardiac output, MPAP mean pulmonary arterial pressure, PAOP pulmonary
artery occlusion pressure, SvO2 mixed venous oxygen saturation, p(v-a)CO2 mixed venous to arterial carbon dioxide partial pressure gradient, NE norepinephrine
p < 0.05 considered as significant
aSignificant changes over time within groups (comparison made with Friedman test and post hoc Bonferroni correction)
*Significant difference between control group and ESM group, respectively at the same time point (comparison made with Mann-Whitney U test)
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and attenuated histological lung damage [42]. Recently, a
growing interest in esmolol, a short-acting selective β1-
blocker has arisen mainly because of its pharmacokinetic
characteristics [36–39]. An elegant experimental septic
shock study found that ESM improves cardiac contract-
ibility and vascular reactivity probably in relation to an
anti-inflammatory effect [37]. In a randomized controlled
study in stable septic shock patients, ESM reduced heart
rate, decreased fluid requirements and lactate levels, and
surprisingly showed a significant effect on mortality [38].
A disproportionate sympathetic response can be detri-
mental to critically ill patients as was demonstrated de-
cades ago in another context such as chronic heart
failure [22, 26]. Therefore, a growing interest in adrener-
gic modulation has arisen [22–26]. The big dilemma is
to what extent can adrenergic modulation or blockade
be accomplished without affecting basic survival re-
sponses especially in systemic hemodynamics. We found
that both DEX and ESM appear to be well tolerated
when started very early after shock onset, not only in
terms of CO, MAP or NE requirements, but also from a
metabolic point of view since both SvO2 and p(v-a)CO2
were comparable to LPS-controls. Furthermore, DEX
and ESM were associated with favorable effects on both
lactate generation and clearance as will be commented
upon below. The few septic shock studies, in which ESM
was assessed, started the drug hours after initial
stabilization [38, 40]. In the case of DEX, this drug is
not frequently used for primary sedation in septic shock
patients due to the risk of inducing hemodynamic in-
stability. DEX and clonidine might have opposite actions
on vasomotor tone, a direct vasopressor, and indirect
vasodilatory effects, with variable impact on MAP.
When administered in healthy volunteers, DEX exerts a
biphasic response, an initial increase in MAP due to
stimulation of postsynaptic α2b receptors followed by a
long-lasting fall in MAP due to its central sympatholytic
action with a decrease in epinephrine and NE blood
levels [43]. Some investigators have tested the hypothesis
that central sympaticolysis might help to restore adren-
ergic vasoconstrictor responsiveness in septic shock by
reversing downregulation of alpha receptors secondary
to high endogenous catecholamines, and some experi-
mental data tend to support this as feasible [27, 44].
However, this effect might take longer time. In any case,
the hemodynamic tolerance exhibited by both drugs in
our study opens new opportunities for research in this
relevant subject.
Septic shock triggers a strong compensatory sympa-
thetic activation with a wide array of circulatory,
Table 3 Evolution of serum lactate, muscle lactate, epinephrine levels, and exogenous lactate clearance at different time points
Control-DEX
Variable Group A B C D pa
Arterial lactate (mmol/L) Control 2.0 ± 0.5 5.1 ± 1.8 8.1 ± 1.7 9.2 ± 1.8 a
DEX 1.7 ± 0.5 3.4 ± 1.9 4.1 ± 1.9* 6.4 ± 3.1 a
Muscle lactate (mmol/L) Control 3.8 ± 2.0 4.6 ± 1.3 5.1 ± 1.3 6.9 ± 3.5 a
DEX 5.2 ± 4.4 4.9 ± 2.1 6.7 ± 3.6 6.7 ± 2.4
Epinephrine levels (ng/ml) Control 5.8 ± 4.3 5.6 ± 4.3 6.9 ± 4.2 7.3 ± 1.4
DEX 4.1 ± 1.8 3.2 ± 1.5 3.9 ± 3.6 4.6 ± 1.3*
Lactate clearance (ml/kg/min) Control 2.43 ± 1.14
DEX 6.97 ± 1.60*
Control-ESM
Variable Group A B C D pa
Arterial lactate (mmol/L) Control 2.0 ± 0.5 5.1 ± 1.8 8.1 ± 1.7 9.2 ± 1.8 a
ESM 1.6 ± 0.4 3.7 ± 0.9 3.6 ± 1.0* 4.5 ± 1.1* a
Muscle lactate (mmol/L) Control 3.8 ± 2.0 4.6 ± 1.3 5.1 ± 1.3 6.9 ± 3.5 a
ESM 3.3 ± 1.7 3.6 ± 3.2 5.0 ± 3.8 5.4 ± 2.6
Epinephrine levels (ng/ml) Control 5.8 ± 4.3 5.6 ± 4.3 6.9 ± 4.2 7.3 ± 1.4
ESM 4.8 ± 3.6 5.8 ± 7.1 9.0 ± 3.2 7.1 ± 2.4
Lactate clearance (ml/kg/min) Control 2.43 ± 1.14
ESM 7.32 ± 2.20*
Values are presented as mean ± standard deviation (SD)
DEX dexmedetomidine, ESM esmolol
p < 0.05 considered as significant
aSignificant changes over time within groups (comparison made with Friedman test and post hoc Bonferroni correction)
*Significant difference between control group and DEX or ESM groups, respectively at the same time point (comparison made with Mann-Whitney U test)
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metabolic and immune effects that could potentially im-
pact lactate production or clearance [22, 26]. Among
metabolic effects, epinephrine stimulates aerobic glycoly-
sis in skeletal muscle cells through β2 stimulation. This
process generates and releases lactate into the systemic
circulation as a metabolic fuel [10, 11]. A dysregulated
sympathetic stress response or exogenous catechol-
amines could also impair hepatosplanchnic or microcir-
culatory flow at the gut or the liver through excessive
vasoconstriction, triggering anaerobic lactate generation
and potentially impairing hepatic lactate clearance [15–
21]. We designed our study to address three potential
sources for persistent hyperlactatemia on which an over-
active sympathetic response could exert some influence.
DEX induced a 37 % reduction in serum epinephrine
levels, but noteworthy, this was not associated to any
negative effect, neither on hemodynamics, nor in muscle
lactate outflow. Muscle lactate production can be
decreased experimentally by different approaches and
inversely, exogenous β2-adrenergic stimulation with
epinephrine and other β2-agonists increases aerobic lac-
tate generation [10, 11]. In this latter case, the threshold
over which epinephrine might hasten muscle lactate out-
flow is unknown but clearly DEX in relatively high doses
did not affect this process.
The effects on the hepatosplanchnic region are of par-
ticular interest. We observed that LPS animals treated
with ESM and DEX exhibited less increase in portal lac-
tate levels as compared with LPS controls. Additionally,
portal venous O2 saturation decreased over time only in
controls, whereas total hepatic blood flow tended to de-
crease in all groups. Progressive gut hypoperfusion even-
tually ameliorated by adrenergic modulation or blockade
could explain these findings. Unfortunately, the study
design does not allow us to affirm this with certainty
since we did not measure mesenteric or mucosal micro-
circulatory flow directly. Clinical and experimental stud-
ies have yielded conflicting results on splanchnic lactate
balance in sepsis [45–54]. While some studies report an-
aerobic lactate generation by the gut as regional flow
Table 4 Evolution of total hepatic blood flow and perfusion parameters at different time points
Control-DEX
Variable Group A B C D pa
SpO2 (%) Control 81 ± 11 82 ± 7.1 78 ± 7.8 68 ± 11 a
DEX 87 ± 6.0 85 ± 7.0 82 ± 8.3 78 ± 16
ShO2 (%) Control 75 ± 7.5 79 ± 5.2 72 ± 4.6 69 ± 14
DEX 76 ± 5.9 76 ± 6.1 74 ± 8.1 68 ± 17 a
Portal vein lactate (mmol/L) Control 2.0 ± 0.5 4.2 ± 1.4 6.4 ± 1.0 8.1 ± 1.1 a
DEX 1.7 ± 0.5 2.9 ± 1.5 3.7 ± 1.8* 6.2 ± 0.9* a
Hepatic vein lactate (mmol/L) Control 1.7 ± 0.5 4.4 ± 1.7 6.0 ± 1.1 7.3 ± 1.2 a
DEX 1.4 ± 0.6 2.8 ± 1.6 3.4 ± 0.4* 5.8 ± 0.8* a
Total hepatic blood flow (ml/kg/min) Control 30 ± 8.8 36 ± 5.4 28 ± 7.7 25 ± 7.9 a
DEX 27 ± 8.1 34 ± 5.6 23 ± 3.9 21 ± 4.9
Control-ESM
Variable Group A B C D pa
SpO2 (%) Control 81 ± 11 82 ± 7.1 78 ± 7.8 68 ± 11 a
ESM 80 ± 6.1 79 ± 8.1 69 ± 12 75 ± 12
ShO2 (%) Control 75 ± 7.5 79 ± 5.2 72 ± 4.6 69 ± 14
ESM 70 ± 11 70 ± 16 68 ± 12 62 ± 23
Portal vein lactate (mmol/L) Control 2.0 ± 0.5 4.2 ± 1.4 6.4 ± 1.0 8.1 ± 1.1 a
ESM 1.1 ± 0.4* 2.4 ± 0.7* 2.9 ± 0.9* 4.0 ± 1.1* a
Hepatic vein lactate (mmol/L) Control 1.7 ± 0.5 4.4 ± 1.7 6.0 ± 1.1 7.3 ± 1.2 a
ESM 1.2 ± 0.4* 2.2 ± 0.6* 2.8 ± 1.0* 3.6 ± 1.4* a
Total hepatic blood flow (ml/kg/min) Control 30 ± 8.8 36 ± 5.4 28 ± 7.7 25 ± 7.9 a
ESM 39 ± 8.0 37 ± 14 32 ± 13 28 ± 11
Values are presented as mean ± standard deviation (SD)
DEX dexmedetomidine, SpO2 portal vein oxygen saturation, ShO2 hepatic vein oxygen saturation, ESM esmolol
p < 0.05 considered as significant
aSignificant changes over time within groups (comparison made with Friedman test and post hoc Bonferroni correction)
*Significant difference between control group and DEX or ESM groups, respectively at the same time point (comparison made with Mann-Whitney U test)
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decreases, other have minimized the contribution of gut-
generated lactate to systemic hyperlactatemia, since
most of this lactate would be normally cleared by the
liver [45–54]. Nonetheless, if hepatic lactate clearance is
simultaneously impaired, the systemic impact of gut-
generated lactate might be higher.
In a previous study using the same model, LPS in-
duced an early and severe impairment in exogenous
whole body net lactate clearance that was not related to
total liver hypoperfusion or evident biochemical dysfunc-
tion [13]. Indeed, the very low porto-hepatic vein lactate
differences suggested at least a liver metabolic inability
to handle increased lactate loads. The decrease in lactate
clearance reached a 10 % of sham values at the end of
the experiments [13]. In the present study, exogenous
lactate clearance fell to extremely low levels in LPS-
controls similarly than in our previous study, but this
decrease was significantly attenuated both in DEX and
ESM groups. The combined effects on gut perfusion and
lactate clearance might explain the impact of DEX and
ESM on serum lactate levels.
How can DEX and ESM actions decrease gut lactate
generation or influence exogenous lactate clearance? We
did not design this study as a mechanistic one, and
therefore we can only speculate about the mechanisms.
α2-agonists such as DEX can attenuate the sympathetic
response to surgery, decreasing circulating catechol-
amine levels in at least 10 to 20 %, but in our LPS model
it was almost 40 % [27, 28]. Interestingly, DEX might
exert opposite actions on vasomotor tone, a direct vaso-
pressor and indirect vasodilatory effects, with variable
impact on MAP [27, 28]. However, some experimental
studies have shown that α2 agonists could have predom-
inantly favorable effects over the gut microcirculation
[33, 34], a particularly vulnerable territory [55]. Yeh et al
found that DEX prevented gut microcirculatory abnor-
malities induced by sympathetic activation after surgical
stress in rats [33]. Miranda et al found a significant at-
tenuation of capillary perfusion deficits with DEX in a
LPS model [34]. Thus, it is possible that the favorable ef-
fect of DEX on portal lactate levels might be conse-
quence of an attenuated adrenergic vasoconstriction on
mesenteric or gut microcirculatory flow. It is more diffi-
cult to explain the effects of ESM since no direct vascu-
lar effect can be postulated. However, some
experimental studies have shown protective vascular or
microcirculatory effects potentially related to immuno-
modulation, or increased release of endothelial nitric
oxide among other actions, but this should be confirmed
by further research [35–38]. It is also well known that
LPS can induce acute portal hypertension resulting in
gut mucosal hypoperfusion [56] and that nonselective β-
blockers might reduce portal hypertension, but this
effect might not be extrapolated to β1-selective blockers.
The favorable impact of DEX and ESM on exogenous
lactate clearance can be hardly explained by
hemodynamic effects, since only a small difference in
total hepatic blood flow compared to controls was ob-
served at the end of the experiments. Potential liver
microcirculatory or cellular effects of DEX and ESM
should be explored in future studies.
We acknowledge several limitations of our study. First,
we did not assess directly gut or liver microcirculation,
thus this precludes us establishing any conclusion on the
microvascular effects of both drugs. Second, we did not
evaluate immunological aspects or biomarkers, eventu-
ally missing the exploration of the impact of adrenergic
modulation at this level in our model. Third, small dif-
ferences in portal and hepatic vein lactate levels between
ESM and controls were observed at baseline and after
shock induction. Biological variability in response to sur-
gical stress or LPS could explain this finding, but the
a
b
c
Fig. 2 Comparison of dexmedetomidine, esmolol and controls in
exogenous lactate clearance (A), cardiac output (B), and total
hepatic blood flow (C) at the end of experiments. Both DEX and
ESM were associated with less impairment in lactate clearance when
compared to controls despite comparable systemic and regional
hemodynamics. DEX dexmedetomidine, ESM esmolol
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strong differences still observed at points C and D sup-
port our conclusions. Fourth, since our study was not
aimed at comparing DEX with ESM, but rather both
drugs against LPS controls, we cannot formulate any
conclusion concerning eventual superiority of one over
the other. Finally, our study can be considered only as
hypothesis-generating and therefore these results should
be confirmed and expanded in further research.
Conclusions
In conclusion, dexmedetomidine and esmolol were well tol-
erated and associated with lower arterial and portal lactate
levels, and less impairment of exogenous lactate clearance
in a model of endotoxic shock. Adrenergic modulation or
blockade appears to be associated with beneficial effects on
gut lactate generation and clearance, and exhibits no nega-
tive impact on systemic hemodynamics at least within the
limits of our experimental model.
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